CXCL13, a well-known marker of inflammation in cancer and CNS infections [32,33], has been suggested as a potential prognostic biomarker for MS, as its levels are extremely high in patients with this clinically unpredictable disease [28,29,30]. The gene discussed is CXCL13; the disease is myeloid sarcoma.